Six months after becoming an LP in Index Ventures' first fund dedicated to life sciences, Johnson & Johnson is making a second move designed to significantly increase both the number of early stage deals it does, and the speed and flexibility with which it does them.

By integrating a variety of stand-alone programs, J&J also hopes to better support the innovation ecosystem on which it and other large pharmas depend.